This trial will answer the question of whether, for patients classified as low risk based on pathologic Complete Response (pCR) following neoadjuvant therapy, 6 months of overall HER2 blockade is an acceptable duration (compared to 12 months).
Contact phone
(517) 364-2811
Contact email
[email protected]
Principal investigator
Dr. Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Breast
Webform